Sensitivity status of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine and sulfadoxine/pyrimethamine in a tribal population of District Sundargarh, Orissa.
In a malaria-endemic area of Orissa, wherein chloroquine has been in use for over thirty years, 58.3% (14/24) P. falciparum cases did not respond to single dose chloroquine (10 mg base/kg) in in-vivo test. With standard dose (25 mg base/kg) 31.2% cases (10/32) showed resistance, i.e. at RI (15.6%), RII (9.4%) and RIII (6.2%) levels. Standard dose was superior in response to the single dose therapy [p < 0.05; chi 2 (df 1) = 4.11]. Out of eight isolates tested in vitro, two showed resistance to chloroquine, five to sulfadoxine/pyrimethamine (SP) but all were sensitive to amodiaquine, quinine and mefloquine. Whereas the standard dose of chloroquine would be a better option in general, in resistant cases, SP, quinine and mefloquine offer an alternative drug choice. The implications of drug resistance in a malaria-control programme and the need to revise drug policy in India are discussed.
Ghosh
S K
SK
Malaria Research Centre (Field Station), Rourkela, India.
Yadav
R S
RS
Sharma
V P
VP
D000655:Amodiaquine / Q000494:pharmacology; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D002738:Chloroquine / Q000494:pharmacology; D004338:Drug Combinations; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D007194:India; D016778:Malaria, Falciparum / Q000188:drug therapy; D015767:Mefloquine / Q000494:pharmacology; D010963:Plasmodium falciparum / Q000187:drug effects*; D011739:Pyrimethamine / Q000494:pharmacology; D011803:Quinine / Q000494:pharmacology; D013413:Sulfadoxine / Q000494:pharmacology
D000962:Antimalarials; D004338:Drug Combinations; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011803:Quinine; D015767:Mefloquine; D011739:Pyrimethamine